MPT Product Development Database

This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
Hormonal/Non-HormonalDelivery RouteDelivery MethodDevelopment Stage
IndicationProduct DeveloperProduct Sponsor/FundingActive Ingredient
Key Word Search   

30 product(s) found

TAF / Elvitegravir Topical Insert

MPT in Development

Active Ingredient:
  • Elvitegravir
  • Tenofovir Alafenamide (TAF)
  • Hormonal/Non-Hormonal:
  • Funding:
  • U.S. Agency for International Development (USAID)
  • Development Stage:
    Clinical – Phase 1 Trial (C1)
    Delivery Route & Method:
    Topical - Fast Dissolve Insert – Vaginal, Rectal
    Mechanism of Action:
    Nucleoside analogue reverse transcriptase inhibitor (NRTI); Integrase strand-transfer inhibitor
    Product Indications:
  • HIV
  • HSV-2
  • Description:
    Solid, tablet-like dosage form for dual-compartment (vaginal or rectal) on-demand use. A Phase I study to assess safety, pharmacokinetics, and pharmacodynamics of the TAF/EVG insert administered vaginally (CONRAD A18-146) was completed in Q1 of 2019; data are expected by Q3 of 2019. A Phase 1 study to assess rectal administration of the insert (MTN-039) is pending initiation in early Q3 2019. A placebo form of this insert is also being evaluated in an international, multi-site acceptability study (MTN-035, DESIRE) comparing three different rectal dosage forms.
    IMPT Secretariat
    1750 Howe Avenue, Suite 550
    Sacramento, CA 95825
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    © Copyright 2019, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.

    The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, an organization dedicated to advancing the comprehensive sexual and reproductive health of women and girls worldwide. CAMI Health is housed at the Public Health Institute (PHI).

    This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.